SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)
Website: www.sinobiopharm.com
(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
COMPLETION OF ENROLLMENT OF THE FIRST PATIENT IN THE PHASE I CLINICAL TRIAL OF LM-2417 "NaPi2b/4-1BB BISPECIFIC ANTIBODY" IN CHINA

The board of directors (the "**Board**") of Sino Biopharmaceutical Limited (the "**Company**", together with its subsidiaries, the "**Group**") announces that the enrollment of the first patient in the Phase 1 clinical trial conducted in China for LM-2417 "NaPi2b/4-1BB bispecific antibody", a National Class 1 innovative drug independently developed by LaNova Medicines Limited ("**LaNova Medicines**", a wholly-owned subsidiary of the Company), has been successfully completed, which marks the official entry into the stage of clinical development for this innovative therapy.

NaPi2b, encoded by the SLC34A2 gene, is a member of the SLC34 family of type II sodium-dependent phosphate transporters and plays a crucial role in regulating phosphate homeostasis in the body. NaPi2b is highly expressed in various malignant tumors, including high-grade serous ovarian cancer, fallopian tube cancer, primary peritoneal cancer, as well as thyroid cancer, breast cancer, and non-squamous non-small cell lung cancer, while its distribution in normal tissues is limited, thus making it a promising target for the anti-tumor treatment. Currently, multiple domestic and overseas companies have made their efforts in the layout of this field, but no related drugs have been approved for marketing.

LM-2417 is a NaPi2b/4-1BB bispecific antibody developed by LaNova Medicines based on the conditionally activated 4-1BB platform, a proprietary platform of LaNova Medicines. Such antibody can specifically bind NaPi2b on the surface of tumor cells and 4-1BB on the surface of immune cells. This mechanism enables the precise activation of immune cells within the tumor microenvironment, thereby enhancing anti-tumor effects. Unlike traditional 4-1BB agonists, LM-2417 selectively activates the signaling pathway of 4-1BB via a NaPi2b-dependent approach, which is expected to significantly minimize the risks of toxicity triggered by non-specific immune activations.

As indicated by the preclinical data, LM-2417 not only induces durable anti-tumor immune memory but also exhibits significant synergy when combined with other immunotherapeutic agents. These features position LM-2417 as a potentially First-in-Class immunotherapy.

This clinical study is an open-label, dose escalation and dose expansion Phase I/II clinical trial evaluating the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of LM-2417 for injection as a monotherapy or in combination with other anti-tumor drugs in patients suffering advanced malignant solid tumors. The Group will continue to rapidly advance the clinical development of this project in anticipation of bringing new options of immunotherapy for clinical use to patients as soon as possible.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 23 September 2025

As at the date of this announcement, the Board of the Company comprises six executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, and Mr. Tian Zhoushan, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.